- Conditions
- Type 1 Diabetes, New Onset
- Interventions
- Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 9 Years to 20 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2017–2040
of 21,025
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Osteoarthritis, Rheumatoid Arthritis
- Interventions
- Mailed Arthritis Self-Management Education
- Behavioral
- Lead sponsor
- University of North Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Hepatitis C Virus (HCV), Hepatitis C Virus (HCV) Infection, HIV (Human Immunodeficiency Virus)
- Interventions
- Physician-Initiated Screening (Conventional Screening), FOCUS (Universal Screening), HepC-EnD (Targeted Screening)
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 6,466 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Gainesville, Florida • Jacksonville, Florida
- Conditions
- Asthma, Obesity
- Interventions
- Roflumilast 500 Mcg Oral Tablet, Placebo oral capsule
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Chicago, Illinois + 3 more
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Malignant Neoplasm, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia
- Interventions
- alvocidib, cytarabine, mitoxantrone hydrochloride, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Madison, Wisconsin
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Teplizumab Herold Regimen, Placebo, Teplizumab 33.3% Herold Regimen, Teplizumab Curtailed Herold Regimen
- Biological · Drug
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 8 Years to 35 Years
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 37 more
- Conditions
- IgM and IgG in Blood
- Interventions
- Rapid antibody test
- Other
- Lead sponsor
- Texas Cardiac Arrhythmia Research Foundation
- Other
- Eligibility
- 16 Years to 85 Years
- Enrollment
- 500 participants
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML), Juvenile Myelomonocytic Leukemia(JMML), Hemoglobinuria, Paroxysmal Nocturnal (PNH), Lymphoma, Non-Hodgkin (NHL), Myelodysplastic Syndrome (MDS)
- Interventions
- Miltenyi Biotec CliniMACS, Stem Cell Transplantation, TBI, systemic chemotherapy and antibodies as follows:
- Device · Procedure · Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Type 1 Diabetes
- Interventions
- Insulin Pump
- Device
- Lead sponsor
- Medtronic MiniMed, Inc.
- Industry
- Eligibility
- 14 Years to 75 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 9
- States / cities
- Escondido, California • Palo Alto, California • Aurora, Colorado + 5 more
- Conditions
- Postmenopausal, Osteopenia, Rheumatoid Arthritis, Osteoporosis
- Interventions
- Etanercept, Denosumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 45 Years to 80 Years · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 2
- States / cities
- Duncansville, Pennsylvania • Dallas, Texas
- Conditions
- Multiple Sclerosis
- Interventions
- Cetirizine, Diphenhydramine
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boca Raton, Florida
- Conditions
- Allergy
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 940 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Remibrutinib (Blinded), Placebo, Remibrutinib (Open Label)
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 18 more
- Conditions
- Allergy
- Interventions
- Short Ragweed Pollen Allergenic Extract, Placebo
- Biological
- Lead sponsor
- Greer Laboratories
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 429 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Warrenton, Virginia
- Conditions
- HIV/AIDS, HIV Infections
- Interventions
- darunavir, Ritonavir, Etravirine
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 49 Years · Male only
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma Refractory, Multiple Myeloma in Relapse
- Interventions
- EZM0414
- Drug
- Lead sponsor
- Epizyme, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 8
- States / cities
- Duarte, California • East Brunswick, New Jersey • New York, New York + 3 more
- Conditions
- HIV Infections
- Interventions
- Cabenuva Scheduling Alerts in the Retention & Huddle modules of the CHORUS App
- Other
- Lead sponsor
- Epividian
- Industry
- Eligibility
- Not listed
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Nelfinavir mesylate, Lamivudine, Stavudine
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Multiple Sclerosis
- Interventions
- Moderate intensity walking exercise
- Behavioral
- Lead sponsor
- Kessler Foundation
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- West Orange, New Jersey
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Cow's Milk Allergy
- Interventions
- DBV1605
- Combination Product
- Lead sponsor
- DBV Technologies
- Industry
- Eligibility
- 29 Days to 24 Months
- Enrollment
- 230 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Tucson, Arizona • San Diego, California + 16 more
- Conditions
- Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Secondary Central Nervous System Lymphoma
- Interventions
- Acalabrutinib
- Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Sacramento, California • Oklahoma City, Oklahoma
- Conditions
- B-cell Non-Hodgkin Lymphoma
- Interventions
- Mosunetuzumab, Polatuzumab Vedotin, Rituxumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • La Jolla, California + 12 more
- Conditions
- Rhinitis, Allergic, Seasonal, Hay Fever
- Interventions
- Ciclesonide, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 6
- States / cities
- Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more